Abbott

Poll Finds Over Half of Texas Voters Support Relaxed Marijuana Laws, Decriminalization Bill Advances

Source Node: https://zephyrnet.com/majority-of-texas-voters-want-less-strict-marijuana-laws-poll-finds-as-decriminalization-bill-advances/
Time Stamp: March 15, 2023 2:05 PM - Modified On: March 15, 2023 - Published By:
Source Cluster:
Published by Plato

The state of Texas is making progress towards marijuana reform. According to a recent poll, over half of Texas voters support relaxing marijuana laws and allowing for decriminalization. This is a significant shift in public opinion, as the state has long been known for its strict stance on marijuana.The poll, conducted by the University of Texas and Texas Tribune, surveyed 1,200 registered voters. It found that 53 percent of respondents supported reducing penalties for marijuana possession. This is a significant increase from the 39 percent who supported similar measures in

Abbott’s MitraClip™ Device Demonstrates Long-Term Benefits in Landmark COAPT™ Trial Results

Source Node: https://zephyrnet.com/late-breaking-data-from-landmark-coapt-trial-show-long-term-benefits-of-abbotts-mitraclip-device/
Time Stamp: March 4, 2023 7:00 PM - Modified On: March 4, 2023 - Published By:
Source Cluster:
Published by Plato

In a landmark clinical trial, Abbott's MitraClip™ device has demonstrated long-term benefits for patients with severe mitral regurgitation (MR). The results of the COAPT™ trial, published in the New England Journal of Medicine, showed that patients who received the MitraClip™ device had significantly improved symptoms and quality of life compared to those who received medical therapy alone. The MitraClip™ device is a minimally invasive treatment option for patients with severe MR. It is designed to reduce the amount of blood that flows backward through the mitral valve, which can cause

COAPT™ Trial Results Demonstrate Long-Term Benefits of Abbott’s MitraClip™ Device

Source Node: https://zephyrnet.com/late-breaking-data-from-landmark-coapt-trial-show-long-term-benefits-of-abbotts-mitraclip-device/
Time Stamp: March 4, 2023 7:00 PM - Modified On: March 4, 2023 - Published By:
Source Cluster:
Published by Plato

for Heart Failure Patients Recent findings from the COAPT™ clinical trial have demonstrated the long-term benefits of Abbott's MitraClip™ device for heart failure patients. The trial, which was conducted by the Cardiovascular Research Foundation, showed that the MitraClip™ device significantly reduced hospitalizations and improved quality of life for patients with heart failure. The MitraClip™ device is a minimally invasive device that is used to treat mitral regurgitation, a condition in which the mitral valve does not close properly and allows blood to flow backward in the heart. The device works

Abbott’s TriClip™ Device Demonstrates Superiority to Medical Therapy for Tricuspid Regurgitation in New Data.

Source Node: https://zephyrnet.com/new-data-show-superiority-of-abbotts-triclip-device-compared-to-medical-therapy-for-tricuspid-regurgitation/
Time Stamp: March 3, 2023 7:00 PM - Modified On: March 3, 2023 - Published By:
Source Cluster:
Published by Plato

Tricuspid regurgitation (TR) is a serious heart condition that affects millions of people worldwide. It occurs when the tricuspid valve, which separates the right atrium and right ventricle, does not close properly, causing blood to flow backward into the right atrium. This can lead to a variety of symptoms, including shortness of breath, fatigue, and an irregular heartbeat. Left untreated, TR can lead to serious complications, including heart failure. Recently, new data has demonstrated the superiority of Abbott's TriClip™ device to medical therapy for treating TR. The TriClip™ device is

Abbott’s TriClip™ Device Demonstrates Superiority to Medical Therapy for Treating Tricuspid Regurgitation in New Data

Source Node: https://zephyrnet.com/new-data-show-superiority-of-abbotts-triclip-device-compared-to-medical-therapy-for-tricuspid-regurgitation/
Time Stamp: March 3, 2023 7:00 PM - Modified On: March 3, 2023 - Published By:
Source Cluster:
Published by Plato

Treating tricuspid regurgitation (TR) is a challenge for cardiologists, as the condition can lead to serious complications and even death. Abbott’s TriClip™ device has emerged as a promising solution to this problem. In a new study, researchers have demonstrated the superiority of the TriClip™ device over medical therapy for treating TR.TR is a condition where the tricuspid valve, which separates the right atrium and right ventricle of the heart, does not close properly. This causes blood to flow backward from the right ventricle into the right atrium, leading to an